1. Academic Validation
  2. Design, Synthesis, and Biological Evaluation of C2-(N-Substituted Amino) Truncated 4'-Thioadenosine Derivatives as A2AAR and A3AR Dual Ligands

Design, Synthesis, and Biological Evaluation of C2-(N-Substituted Amino) Truncated 4'-Thioadenosine Derivatives as A2AAR and A3AR Dual Ligands

  • ACS Med Chem Lett. 2025 Nov 14;16(12):2512-2519. doi: 10.1021/acsmedchemlett.5c00601.
Misuk Joung 1 Hongseok Choi 1 Minjae Kim 1 Seung Woo Kim 1 Gibae Kim 1 Vikas R Aswar 1 Seungwon Baek 2 Hyun-Tae Kim 2 Won-Ki Huh 2 3 Lak Shin Jeong 1 4
Affiliations

Affiliations

  • 1 College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea.
  • 2 Department of Biological Sciences, Seoul National University, Seoul, 08826, Republic of Korea.
  • 3 Institute of Biodiversity, Seoul National University, Seoul, 08826, Republic of Korea.
  • 4 Future Medicine Co., Ltd, Seongnam, Gyeonggi-do 13449, Republic of Korea.
Abstract

Dual modulation of adenosine A2A and A3 receptors (ARs) is an emerging strategy for disorders involving receptor interplay. We designed and synthesized truncated 4'-thioadenosines bearing a C2-NH-R linker to enable dual A2A/A3 AR engagement. Structure-activity trends showed that aryl amine analogues tended to display affinity toward both A2A and A3 receptors, whereas aliphatic ones were inactive at both receptors. Ortho substitution in aryl amine analogues consistently enhanced binding affinity relative to meta or para substitution. Lead 4q (σ-morpholinophenyl) exhibited high affinity for hA2AAR and hA3AR (K i = 15.0 ± 1.2 nM; 4.5 ± 0.5 nM). Computational modeling supported orthosteric binding at both receptors, and cAMP assays revealed inverse agonism at hA2AAR (-19%) and antagonism at hA3AR (69% inhibition of the NECA response). These findings suggest that the C2-NH-R-modified, truncated 4'-thioadenosine as a compact scaffold for A2A/A3 binding and highlight 4q as a dual ligand that may contribute to future AR ligand research.

Keywords

Adenine derivatives; Dual ligand; Nucleoside derivatives; Structure−Activity Relationship.

Figures
Products